Crawford et al., (2024, May). “Double-Blind, Multiple Ascending Dose, Safety, Pharmacokinetic and Body Composition Study of Enobosarm in Healthy Young and Older Men”. Poster presented at the 2024 American Association of Clinical Endocrinology, New Orleans, LA. May 2024|Enobosarm, Obesity|
Steiner et al., (2024, May). “Advancing enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for potentially higher quality weight loss”. Slides presented at the 2024 GLP-1-Based Therapeutics Summit in Philadelphia, PA. May 2024|Enobosarm, Obesity|
Barnette al., (2024, May). “A Phase 2 Trial to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management”. Poster presented at the 2024 GLP-1-Based Therapeutics Summit in Philadelphia, PA. May 2024|Enobosarm, Obesity|
Palmieri et al., Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024 Mar;25(3):317-325. March 2024|Cancer, Enobosarm|
K O Böker et al., Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model. Endocrine. 2023 Sep;81(3):579-591. September 2023|Enobosarm, Obesity|
